Molecular Oncology Overview

Principles

Definition

Molecular oncology is a field of biomedical research dedicated to investigating the molecular and genetic alterations that underlie cancer development, progression, and behavior. Its primary aim is to identify specific molecular targets for diagnosis, prognosis, and the development of targeted therapies.

Ontological type

Targeted Therapies

Core Pathways

Biomarkers and Stratification

Key developments

Key Figures

Mechanism-Guided Foundations era

George J. Todaro [1] was a leading figure whose work spanned Albert Einstein College of Medicine [3] and Icahn School of Medicine at Mount Sinai [4] during the Mechanism-Guided Foundations era. His key contribution during this era was the 1973 paper In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2 [7], which established cell lines as reproducible model systems for mechanistic interrogation of tumor biology. Stuart A. Aaronson [2] was affiliated with Harvard University [5] and the University of California, San Francisco [6] during this era. Stuart A. Aaronson [2] co-authored the same 1973 paper In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors2 [7], enabling mechanistic studies and establishing foundational tumor models for drug discovery.

Pathway-Driven Stratification era

Tetsuya Mitsudomi [1] is a leading figure in molecular oncology during Pathway-Driven Stratification, with affiliations at Harvard University [3] and The University of Texas Southwestern Medical Center [4] in this era. His key contributions in this era include advancing pathway-informed strategies for NSCLC through the Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [7], which demonstrated that EGFR mutations predict responsiveness to targeted therapy and enabled biomarker-driven trial design. Yasushi Yatabe [2] is another leading figure of this era, with affiliations at University of Helsinki [5] and University of Southern California [6]. His work, including co-authorship of the Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [7], helped translate pathway biomarkers into clinical practice and diagnostics, catalyzing biomarker-driven therapy in NSCLC during this era.

Genomics-Driven Precision Oncology era

Yi‐Long Wu [1] has been active in leading cancer genomics-driven precision oncology through roles associated with the Shanghai Medical College of Fudan University [3] and Northwestern University [4] in this era. His key contributions include the OPTIMAL trial (CTONG-0802) [7], a multicentre study comparing Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer, which demonstrated the potential of EGFR-targeted therapy and helped establish biomarker-driven strategies in this genomics era. Hans Clevers [2] has anchored his work in the Institute of Cancer Research [5] and Harvard University [6] during this era, contributing to tumor biology and organoid-based modeling that shapes precision oncology. His notable contribution includes the 2017 paper Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer [8], which illuminated diverse stromal cell populations and their implications for tumor behavior and therapeutic targeting in a genomics-guided era.